Compare EPAM Systems Inc (EPAM) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPAM Systems Inc vs Gilead Sciences, Inc. — how do they compare? EPAM Systems Inc trades at $113.24 (market cap $5.87B), while Gilead Sciences, Inc. trades at $151.17 (market cap $182.40B). The key difference: Gilead Sciences, Inc. is far larger — about 31.1× EPAM Systems Inc's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while EPAM Systems Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold EPAM Systems Inc for 37 Days and Gilead Sciences, Inc. for 111 Days on average.
| EPAM | GILD | |
|---|---|---|
Market Cap | $5.87B | $182.40B |
Volume | 847,420 | 4,469,821 |
Sector | Technology | Health |
52-Week High | $221.40 | $155.80 |
52-Week Low | $76.04 | $117.18 |
Typical Hold Time | 37 Days | 111 Days |
Enterprise Value | $5.24B | $205.46B |
Dividend Yield | — | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPAM Systems trades at $113.86, up 5.11% today, with strong technical momentum as the stock approaches resistance near $115. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.46B in 2025, though net margins compressed to 6.92%. Recent news highlights EPAM's cloud infrastructure achievements and activist investor pressure for share buybacks.
The outlook remains cautiously optimistic with a consensus price target of $119 offering 4.5% upside. Key risks include North American growth slowdown and AI disruption to legacy services. Analyst sentiment is predominantly bullish (59% Buy ratings), but investors should monitor Q3 earnings and management's response to shareholder value concerns.
Gilead Sciences (GILD) trades at $147.10, up 0.17% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings have mostly beaten expectations, though Q2 2026 saw a significant loss. The company maintains robust operating cash flow and has expanded access to its HIV prevention drug lenacapavir in Latin America, signaling growth potential in its core franchises.
The outlook is positive given analyst buy ratings and a $151.57 price target, but risks include negative net income margin and ROE in 2026, high debt levels, and reliance on pipeline success. The stock offers value if HIV and oncology advances materialize, yet investors face volatility from earnings inconsistencies and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
